This article reports preliminary results from a pilot study started in 1986 on patients with acute myeloblastic leukemia treated for several months with low-dose arabinosylcytosine and 1(OH)D3. During treatment or at the time of relapse, a monoblastic component was frequently found. A high percentage of patients were P-170-positive. In 2 patients it was possible to show that blasts, previously P-170-negative, became positive after treatment. In these 2 patients, failure of clinical response to antileukemic therapy was associated with this phenotype. The addition of the revertant drug nicardipine to the previously inactive treatment induced a partial response. Thus, previously reported in vitro observations on the differentiating activity of vitamin D3 metabolites, possible induction of multidrug chemoresistance by differentiating agents and the revertant activity of the Ca++ antagonist nicardipine appear to be confirmed in vivo in the reported patients.

Vitamin D3 Administration and Multidrug Resistance in Acute Nonlymphoblastic Leukemia / M., Petrini; F., Caracciolo; G., Carulli; Conte, Angela; A., Sabbatini; L., Mattii; B., Grassi. - In: ACTA HAEMATOLOGICA. - ISSN 0001-5792. - STAMPA. - 89:(1993), pp. 184-188.

Vitamin D3 Administration and Multidrug Resistance in Acute Nonlymphoblastic Leukemia

CONTE, Angela;
1993

Abstract

This article reports preliminary results from a pilot study started in 1986 on patients with acute myeloblastic leukemia treated for several months with low-dose arabinosylcytosine and 1(OH)D3. During treatment or at the time of relapse, a monoblastic component was frequently found. A high percentage of patients were P-170-positive. In 2 patients it was possible to show that blasts, previously P-170-negative, became positive after treatment. In these 2 patients, failure of clinical response to antileukemic therapy was associated with this phenotype. The addition of the revertant drug nicardipine to the previously inactive treatment induced a partial response. Thus, previously reported in vitro observations on the differentiating activity of vitamin D3 metabolites, possible induction of multidrug chemoresistance by differentiating agents and the revertant activity of the Ca++ antagonist nicardipine appear to be confirmed in vivo in the reported patients.
89
184
188
Vitamin D3 Administration and Multidrug Resistance in Acute Nonlymphoblastic Leukemia / M., Petrini; F., Caracciolo; G., Carulli; Conte, Angela; A., Sabbatini; L., Mattii; B., Grassi. - In: ACTA HAEMATOLOGICA. - ISSN 0001-5792. - STAMPA. - 89:(1993), pp. 184-188.
M., Petrini; F., Caracciolo; G., Carulli; Conte, Angela; A., Sabbatini; L., Mattii; B., Grassi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/736669
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact